Tevogen Inc.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. The company's website is www.tevogen.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tevogen Inc. does
In the company’s own words
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. The company's website is www.tevogen.com.
The company's core technology platform, ExacTcell, represents a proprietary approach to developing allogeneic CD8+ cytotoxic T lymphocyte therapies that target multiple, precisely defined antigenic peptides. Unlike genetically engineered CAR-T cell therapies, ExacTcell utilizes naturally occurring, unmodified T cells sourced from healthy donors and expanded to target specific viral or malignant cell targets. The technology enables production of hundreds of doses from a single donor, facilitating off-the-shelf availability and rapid administration in outpatient settings.
Tevogen's lead product candidate, TVGN 489, is an allogeneic CD8+ T cell therapy initially developed to address unmet treatment needs in immunocompromised and high-risk elderly COVID-19 patients, with additional development for Long COVID treatment and prevention. The company completed a Phase 1 proof-of-concept clinical trial in January 2023, demonstrating safety and rapid viral load reduction without dose-limiting toxicities. The trial results were published in Blood Advances following peer review. The company plans to advance TVGN 489 through pivotal trials in COVID-19 patients with B cell malignancies and other vulnerable populations.
Beyond TVGN 489, Tevogen is leveraging ExacTcell to develop a pipeline of product candidates targeting infectious diseases, oncology, and other conditions. The company is exploring artificial intelligence applications through its Tevogen.AI initiative, including enrollment in the Microsoft for Startups program, to accelerate target detection and product development.
Tevogen operates as a smaller reporting company and emerging growth company. The company is pursuing manufacturing capability development and strategic partnerships to support clinical and commercial supply of its cell therapy products. In March 2026, the company entered into a letter of intent to acquire a greater than fifty percent economic ownership stake in a clinical research organization.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- WARREN, NJ
- Fiscal year end
- December
- CIK
- 1860871
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tevogen Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tevogen Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tevogen Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tevogen Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tevogen Inc.'s last four quarterly filings that the numbers alone won't show?”